3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
3
Myelodysplastic Syndromes
2
Hematologic Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic-Myeloproliferative Diseases
1
Mycoses
1
Mucormycosis
1
Genetic Predisposition to Disease
1
Candidiasis
1
Breast Neoplasms
1
Aspergillosis
1
Interventions
pembrolizumab
57
Carboplatin
34
Paclitaxel
24
Cyclophosphamide
23
Capecitabine
18
sacituzumab govitecan
16
Specimen Handling
15
130-nm albumin-bound paclitaxel
15
toripalimab
11
Drug Therapy
11
Biopsy
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Taxes
9
Epirubicin
9
durvalumab
8
Albumin-Bound Paclitaxel
8
olaparib
7
camrelizumab
7
Gemcitabine
7
Doxorubicin
7
Docetaxel
7
fludarabine
6
famitinib
5
Nivolumab
5
Injections
5
atezolizumab
4
abemaciclib
4
Trastuzumab
4
Standard of Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Breast Neoplasms
×
posaconazole
×
Clear all
NCT06802757
2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2
Recruiting
72 enrolled